PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma

NCT ID: NCT02288897

Last Updated: 2022-01-19

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE3
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-04-30
• Study Completion Date: 2019-09-30

Brief Summary

This is an international multicenter, open-label, randomized controlled trial (RCT) of single-agent intralesional PV-10 versus systemic chemotherapy or intralesional oncolytic viral therapy to assess treatment of locally advanced cutaneous melanoma in patients who (1) are not candidates for targeted therapy and (2) are not candidates for an immune checkpoint inhibitor. Subjects in the comparator arm will receive the Investigator's choice of dacarbazine (DTIC), temozolomide (TMZ) or intralesional talimogene laherparepvec as determined by Investigator preference and standard of care in the Investigator's country or region. Effectiveness will be assessed by comparison of progression-free survival (PFS) between all intent-to-treat (ITT) subjects in the two study treatment arms.

Detailed Description

Subjects will be randomized using a 2:1 treatment allocation (i.e. two-thirds of the subjects will receive PV-10).

Subjects in the comparator arm who have completed at least 1 cycle of study treatment and who meet the study protocol definition of disease progression but do not have evidence of visceral metastases will be eligible to enter the crossover portion of the study and receive PV-10. Subjects crossing over must meet all study inclusion and exclusion criteria for clinical laboratories, thyroid function, concurrent or intercurrent illness and pregnancy at the time of crossover.

Assessment of progression will be performed by an Independent Review Committee (IRC) based on Response Evaluation Criteria in Solid Tumors (RECIST) ver. 1.1 criteria. Events signaling progression include increase in size and/or number of lesions, distant or nodal disease progression, or death. All secondary endpoints involving disease response and progression will be based on the IRC determination.

An interim assessment of efficacy and safety will be performed by the IRC when 50% of the events required for the primary endpoint have occurred.

Conditions

Cutaneous Melanoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

PV-10

Subjects will receive intralesional PV-10 to all Study Lesions on study Day 1. PV-10 should be re-administered at 28-day intervals until complete response, disease progression or study termination occurs.

Group Type: EXPERIMENTAL

PV-10 (10% rose bengal disodium)

Intervention Type: DRUG

Chemotherapy or Oncolytic Viral Therapy

Subjects will receive (a) dacarbazine (intravenously at 850 m/m2) or temozolomide (orally at 200 mg/m2 daily for 5 consecutive days), administered at consecutive 28-day intervals, or (b) intralesional talimogene laherparepvec administered on an initial 21 interval followed by consecutive 14 day intervals, until complete response, disease progression or study termination occurs.

Group Type: ACTIVE_COMPARATOR

Dacarbazine, temozolomide or talimogene laherparepvec

Intervention Type: DRUG

Interventions

PV-10 (10% rose bengal disodium)

Intervention Type: DRUG

Dacarbazine, temozolomide or talimogene laherparepvec

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Age 18 years or older, male or female

2. Histologically or cytologically confirmed melanoma

3. Recurrent, satellite or in-transit locally advanced cutaneous or subcutaneous melanoma metastases (i.e., American Joint Committee on Cancer (AJCC) Stage IIIB, IIIC or Stage IV M1a with no active nodal metastases)

4. At least 1 measurable Target Lesion that can be accurately measured by calipers or computed tomography (CT) consisting of:

• at least one cutaneous lesion (each lesion ≥ 10 mm in longest diameter or up to 5 lesions having a sum of longest diameters ≥ 10 mm); and/or
• at least one subcutaneous lesion (each lesion ≥ 10 mm in longest diameter by CT);
• where Target Lesions should be at least 10 mm from any other lesion

5. No lesion > 50 mm in longest diameter; and no more than 50 lesions

6. Calculated required PV-10 dose ≤ 15 mL (based on total tumor burden)

7. Performance Status: Eastern Cooperative Oncology Group (ECOG) 0-2

8. Not a candidate for treatment with an immune checkpoint inhibitor (e.g., failed or did not tolerate prior therapy, or due to co-morbidities, pre-existing autoimmune disease, drug unavailability or standard of care)

9. Not a candidate for targeted therapy with BRAF or combined BRAF/MEK inhibitors (e.g., failed or did not tolerate prior therapy, BRAF V600 wild-type or due to drug unavailability or standard of care)

10. Clinical Laboratories:

• Absolute neutrophil count (ANC) ≥ 1.5 x 10^9/L and platelet count ≥100 x 10^9/L
• Creatinine ≤ 3 times the upper limit of normal (ULN)
• Estimated creatinine clearance (CrCl) or estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m2
• Total bilirubin ≤ 3 times the upper limit of normal (ULN)
• Aspartate transaminase (AST), alanine transaminase (ALT) and alkaline phosphatase (ALP) ≤ 5 times the upper limit of normal (ULN)
• Lactate dehydrogenase (LDH) ≤ 2 times the upper limit of normal (ULN).

11. Thyroid function abnormality ≤ Grade 2

12. Candidate for at least one comparator drug:

• Subjects must be candidates for at least one of the designated comparator drugs

Exclusion Criteria

1. Presence or history of visceral melanoma metastasis

2. Presence of active nodal metastases (e.g., radiologic or clinical evidence of current nodal disease)

3. Presence of more than 50 melanoma lesions

4. Radiation therapy to any Study Lesion within 6 weeks of initial study treatment.

5. Chemotherapy or other systemic cancer therapy within 4 weeks of initial study treatment (6 weeks for nitrosoureas or mitomycin), or regional chemotherapy (limb infusion or perfusion) within 12 weeks of initial study treatment

6. Immunotherapy for cancer within 4 weeks of initial study treatment

7. Local treatment (e.g., surgery, cryotherapy, laser ablation) to any Study Lesion within 4 weeks of initial study treatment

8. Anti-tumor vaccine therapy within 6 weeks of initial study treatment.

9. Investigational agents within 4 weeks of initial study treatment.

10. Concurrent or Intercurrent Illness:

• Impaired wound healing or other extremity complications due to diabetes mellitus in subjects whose Study Lesions are located in an extremity
• Severe peripheral vascular disease in subjects whose Study Lesions are located in an extremity
• Significant concurrent or intercurrent illness, psychiatric disorders, or alcohol or chemical dependence that would, in the opinion of the Investigator, compromise the subject's safety or compliance or interfere with interpretation of study results.
• Uncontrolled thyroid disease or cystic fibrosis
• Clinically significant acute or unstable cardiovascular, cerebrovascular (stroke), renal, gastrointestinal, pulmonary, immunological, endocrine, or central nervous system disorders

11. Pregnancy:

• Female subjects who are pregnant or lactating
• Female subjects who have positive serum pregnancy test taken within 14 days of study treatment
• Female subjects of child-bearing potential who are unwilling to use highly effective contraception (e.g., combined (estrogen and progestogen containing) or progestogen-only hormonal contraceptives, intrauterine devices, bilateral tubal ligation, vasectomized partner, sexual abstinence or equivalent measures) for the duration of study treatment

12. Contraindication for all comparators:

• Subjects with contraindications to all of the designated comparator drugs

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Provectus Biopharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Eric Wachter, Ph.D.

Role: STUDY_DIRECTOR

Provectus Biopharmaceuticals, Inc.

Sanjiv Agarwala, M.D.

Role: PRINCIPAL_INVESTIGATOR

St Luke's University Hospital and Health Network

Locations

Sharp Memorial Hospital - Clinical Oncology Research

San Diego, California, United States

Mount Sinai Comprehensive Cancer Center

Miami Beach, Florida, United States

Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Washington University School of Medicine - Dermatology

St Louis, Missouri, United States

Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, United States

Atlantic Health System

Morristown, New Jersey, United States

Wake Forest Baptist Health

Winston-Salem, North Carolina, United States

Oklahoma Cancer Specialists and Research Institute

Tulsa, Oklahoma, United States

St Luke's University Hospital and Health Network

Easton, Pennsylvania, United States

Penn State Hershey Cancer Institute

Hershey, Pennsylvania, United States

M.D. Anderson Cancer Center

Houston, Texas, United States

Huntsman Cancer Institute

Salt Lake City, Utah, United States

Unité Cancéro-Dermatologie, Hôtel-Dieu CHU Nantes

Nantes, , France

Institut Claudius Regaud, IUCT ONCOPOLE

Toulouse, , France

Klinik für Dermatologie, Venerologie und Allergologie Charite Universitätsmedizin Berlin

Berlin, , Germany

Klinik für Dermatologie Universitätsklinikum Essen Studienzentrum

Essen, , Germany

Klinik für Dermatologie, Venerologie und Allergologie Universitätsklinikum Schleswig-Holstein Hautkrebszentrum

Kiel, , Germany

Hautklinik Klinikum der Johannes Gutenberg Universität Hautkrebszentrum

Mainz, , Germany

IRCCS Instituto Nazionale Tumori "Fondazione Giovanni Pascale"

Napoli, , Italy

Istituto Dermopatico dell'Immacolata (IDI IRCCS)

Rome, , Italy

Azienda Sanitaria Azienda Ospedaliera Universitaria Senese

Siena, , Italy

Centro de Estudios y Prevención del Cancer A.C.

Juchitán de Zaragoza, Oaxaca, Mexico

Neurociencias Estudios Clínicos S.C.

Culiacán, Sinaloa, Mexico

Countries

United States; France; Germany; Italy; Mexico

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

PV-10-MM-31

Identifier Type: -

Identifier Source: org_study_id